Dr. Vince Clinical Research

What Dr. Vince Clinical Research does

Dr. Vince Clinical Research (DVCR) is a privately held, physician-led contract research organization (CRO) specializing in early-phase (Phase I-II) clinical trials for biopharmaceutical sponsors. Founded in 2001 by Dr. Brad Vince as Vince & Associates Clinical Research and headquartered in Overland Park, Kansas, the company operates a 100-bed clinical pharmacology unit (CPU) with luxury amenities and eight private research suites for overnight domiciling, a DEA-registered cGMP-compliant pharmacy with ISO 5 clean room for Schedule I-V controlled substance handling, and an in-house CAP-accredited and CLIA-compliant clinical laboratory. Approximately 250 employees support a vertically integrated operating model, with the new 5,000-square-foot administration building opened in July 2025 providing additional capacity.

DVCR delivers full-service CRO capabilities including project management, data management, biostatistics and statistical programming, PK/PD analysis and modeling, medical and clinical monitoring, medical writing, central laboratory services, and clinical monitoring, with C-DISC compliant eCRFs and SDTM terminology. Therapeutic-area strengths span CNS/neuroscience (led by SVP Dr. Sheldon Preskorn), respiratory (led by PI Dr. Steven Hull), cardiometabolic and obesity, substance abuse disorders (including Human Abuse Potential studies), allergy and immunology, and pain. The company also operates a multi-site trial network of 50+ strategic site partners across North America for Phase I-III multi-site trials, and runs specialized pharmacology studies including QT/TQT cardiac safety (in partnership with Clario for centralized ECG), drug-drug interaction, food effect, renal/hepatic impairment, and abuse liability assessments.

Revenue is generated through professional service contracts with biopharmaceutical sponsors on a quote-based pricing model; CRO service pricing is not publicly disclosed. Clinical study volunteer compensation — ranging from $4,250 to $15,000 per study depending on complexity and duration — is a cost center, not a revenue stream. The go-to-market combines direct enterprise sales through a dedicated sponsor portal (sponsors.drvince.com), an event-driven presence at industry conferences and educational webinars, and consumer-facing volunteer recruitment through the main website and social channels. DVCR is described as privately owned with no board of directors and no disclosed venture capital or private equity backing, indicating founder-controlled ownership under Dr. Vince as CEO and Chief Medical Officer.

Name

Dr. Vince Clinical Research

Legal name

Dr. Vince Clinical Research, LLC

Website

https://drvince.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Dr. Vince Clinical Research (DVCR) is a privately held, physician-led contract research organization specializing in early-phase (Phase I-II) clinical trials for biopharmaceutical sponsors, operating a 100-bed clinical pharmacology unit in Overland Park, Kansas with approximately 250 employees.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Early-Phase Clinical Research)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Contract research organization
• Early phase clinical trials
• Clinical pharmacology unit
• Biopharmaceutical research services
• First-in-human studies

Headquarters

HQ city

Overland Park

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. CRO Services: Full-service contract research organization providing comprehensive clinical trial services to biopharmaceutical sponsors including project management, data management, biostatistics, PK/PD analysis, medical monitoring, medical writing, clinical pharmacology unit access, and site management services. Revenue generated through service contracts for Phase I-II clinical trials.
2. Clinical Study Volunteer Compensation: DVCR compensates clinical study participants (volunteers) for their participation in trials, ranging from $4,250 to $15,000 depending on study complexity and duration. This is a cost center rather than revenue source.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization that conducts Phase I-IIa clinical trials for biopharmaceutical sponsors. The company operates a 100-bed clinical pharmacology unit with cGMP-compliant pharmacy and in-house CAP/CLIA-accredited clinical laboratory, and delivers integrated services including project management, data management, biostatistics, PK/PD analysis, medical monitoring, medical writing, central laboratory, and multi-site trial management across therapeutic areas such as CNS, respiratory, cardiometabolic/obesity, substance abuse, and immunology.

Product overview

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase clinical trials. The company operates as a unified platform offering comprehensive clinical trial services including a 100-bed clinical pharmacology unit, project management, data management, biostatistics, PK/PD analysis, medical monitoring, medical writing, and central laboratory services. The portfolio includes specialized study types (Drug-Drug Interaction, QT/TQT, Food Effect, Human Abuse Potential, Renal/Hepatic Impairment studies) across therapeutic areas (CNS/Psychiatry/Neurology, Respiratory, Cardiometabolic/Obesity, Substance Abuse Disorders, Allergy/Immunology, Pain). DVCR manages multi-site Phase I-III trials through a network of over 50 strategic site partners across North America, delivering 'Smarter Faster Data' to biopharmaceutical sponsors.

Differentiator

Problem solved

Functional benefit

Products and services

• Full-Service CRO Solutions Comprehensive clinical trial services integrating project management, data management, biostatistics, statistical programming, PK/PD analysis, medical writing, clinical monitoring, medical monitoring, and site feasibility and management for biopharmaceutical sponsors running Phase I-II clinical programs.
• Clinical Pharmacology Unit (CPU) Services Access to a 100-bed overnight-confinement Phase I unit in Overland Park, Kansas, including 8 private research suites for individual domiciling, supportive of first-in-human, SAD/MAD, food effect, DDI, QT/TQT, and bioequivalence studies.
• Phase I-II Multi-Site Trial Management Coordination of multi-site Phase I-III studies in patients, specialty populations, and healthy normal volunteers via DVCR's Lead Site Model and standardized conduct and training across its strategic site network.
• Central Laboratory Services In-house CAP- and CLIA-compliant central laboratory offering customizable kits, next-day turnaround times, proactive shipment monitoring, and real-time data integration to streamline multi-site trials.
• Volunteer Recruitment and Retention Services Recruitment and retention services for healthy volunteers and patient populations, including pre-registration, referral programs, and study-specific enrollment campaigns, supporting rapid enrollment into early-phase trials.
• Substance Abuse Disorder Studies Clinical trials in substance use disorders, including Human Abuse Potential and Human Abuse Liability studies conducted under DEA registration for Schedule I-V controlled substances, supported by DVCR's cGMP pharmacy with controlled-substance safe.
• Tobacco and Nicotine Harm Reduction Studies Clinical and behavioral studies supporting Premarket Tobacco Product Application (PMTA) submissions, including specialized assessments in adult smokers for tobacco harm reduction programs.
• Respiratory Clinical Trials Early-phase respiratory clinical trials led by a board-certified pulmonologist, including FIH, SAD, MAD, and NDA-enabling clinical pharmacology studies for asthma, COPD, and other pulmonary conditions.
• Cardiometabolic and Obesity Research Early-phase clinical research in obesity and metabolic drug development, including next-generation obesity and cardiometabolic therapies, with PI support from board-certified obesity medicine physicians.
• CNS, Psychiatry and Neurology Trials Early-phase clinical trials in CNS, psychiatry, and neurology led by Dr. Sheldon Preskorn, covering major depressive disorder and other neuroscience indications.
• Early QT and Thorough QT (TQT) Cardiac Safety Studies Early QT and Thorough QT cardiac safety studies leveraging DVCR's partnership with Clario to deliver centralized ECG data collection using Surveyor technology, Holter monitoring, and regulatory submission support.
• Drug-Drug Interaction (DDI) Studies Drug-drug interaction studies evaluating inhibition and induction potential of investigational drugs, including cytochrome P450 enzyme and transporter-mediated interactions using cocktail approaches.
• Food Effect Studies Clinical pharmacology studies evaluating the effect of food on investigational drug pharmacokinetics and bioavailability.
• Hepatic Impairment Studies Clinical pharmacology studies enrolling subjects with hepatic impairment to characterize the impact of liver dysfunction on drug pharmacokinetics and dosing.
• Renal Impairment Studies Clinical pharmacology studies enrolling subjects with renal impairment to characterize the impact of kidney dysfunction on drug pharmacokinetics and dosing.
• Human Abuse Potential (HAP) Studies Human Abuse Potential studies for controlled substances using specialized subjective data collection methodologies to support regulatory abuse liability assessments.
• Pharmacokinetic (PK) Studies Pharmacokinetic studies including noncompartmental analysis and pharmacokinetic profiling to characterize absorption, distribution, metabolism, and excretion of investigational drugs.

Quantifiable outcome

• Delivered successful Phase 1a FIH study for Enveda's ENV-294 with favorable safety, tolerability, and PK profile supporting advancement to Phase 1b
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• EnvedacoreStrategic or Co-development Partner · 16 September 2025DVCR conducted Phase 1a FIH study and Phase 1b multi-site study for Enveda's ENV-294, a first-in-class anti-inflammatory drug candidate for atopic dermatitis. The partnership includes continued collaboration on early clinical development of ENV-294 and other pipeline programs.
• ClariocoreTechnology or IntegrationStrategic partnership for cardiac safety assessments in clinical trials. Clario provides centralized ECG collection using Surveyor technology, Holter monitoring services, and regulatory submission support for QT evaluation studies. DVCR leverages Clario's expertise for Thorough QT (TQT) studies and early phase QT assessments.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Celerion: Celerion is one of the largest dedicated early-phase clinical pharmacology CROs globally, with extensive CPU capacity and Phase I expertise. It is the closest direct competitor to DVCR in the early-phase clinical pharmacology unit segment.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized, scientifically focused CRO with deep CNS, cardiometabolic, and early-phase capabilities. It competes directly with DVCR for complex Phase I-II trials in CNS and specialty populations.
• CTI Clinical Trial & Consulting Services: CTI is a privately held CRO specializing in early-phase clinical research across multiple therapeutic areas including CNS, infectious disease, and transplant. Like DVCR, it emphasizes deep scientific expertise and Phase I-II execution.

Regional players

• Altasciences (Algorithme Pharma): Altasciences is a Canadian-based early-phase CRO offering clinical pharmacology, bioanalysis, and manufacturing services. It is a strong regional peer to DVCR in North American early-phase clinical research.

Broad incumbents

• Medpace: Medpace is a mid-sized full-service CRO with growing Phase I capability and an integrated multi-therapeutic platform. It competes with DVCR for biopharma sponsors seeking integrated Phase I-III execution.
• ICON plc: ICON is one of the world's largest CROs offering end-to-end Phase I-IV services, including early-phase units via its PRA Health Sciences acquisition. It is a broad incumbent competing for the same biopharma sponsors as DVCR.
• IQVIA: IQVIA is the largest global CRO with extensive early-phase capabilities and integrated real-world evidence offerings. It is a broad incumbent that competes for sponsor wallet share that DVCR also targets.
• Thermo Fisher Scientific (PPD): PPD, now part of Thermo Fisher Scientific, is a leading global CRO with Phase I-IV capabilities and central laboratory services. It is a broad incumbent competing with DVCR for integrated biopharma study programs.
• Syneos Health: Syneos Health is a large full-service biopharmaceutical services organization offering clinical development and commercial services. It is a broad incumbent that competes with DVCR for Phase I-III biopharma programs.
• Labcorp Drug Development (Covance): Labcorp Drug Development (formerly Covance) offers Phase I-IV CRO services plus central laboratory capabilities—a direct overlap with DVCR's integrated CPU plus central lab model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• Xtwitter.com/VinceClinical
• YouTubeyoutube.com/@Dr.VinceClinicalResearch
• Facebookfacebook.com/drvinceclinicalresearch
• LinkedInlinkedin.com/company/dvcr
• Instagraminstagram.com/drvinceclinicalresearch

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Vince Clinical Research